Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.
Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
by Zacks Equity Research
Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
by Zacks Equity Research
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.
CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
by Zacks Equity Research
Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.
FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
by Zacks Equity Research
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 10.17% and 38.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
by Zacks Equity Research
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
by Zacks Equity Research
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
PepGen (PEPG) Down on Clinical Hold for DM1 Candidate
by Zacks Equity Research
PepGen (PEPG) shares fall after FDA places clinical hold on a study evaluating potential treatment for myotonic dystrophy.
J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH
by Zacks Equity Research
J&J (JNJ) submits a new drug application for a single tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
by Zacks Equity Research
Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
by Zacks Equity Research
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
by Zacks Equity Research
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
by Zacks Equity Research
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
by Zacks Equity Research
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.
Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use
by Zacks Equity Research
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 210.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.